Gold bars to be exempt from tariffs, White House clarifies
Radiopharm Theranostics Ltd, a company specializing in pharmaceutical preparations, announced on Wednesday that it has commenced patient dosing in a therapeutic trial involving its investigational drug, 177Lu-RAD202. The announcement was made through a public notice to the Australian Securities Exchange.
This trial marks the first instance of patient dosing with 177Lu-RAD202, a radiopharmaceutical under investigation for its potential therapeutic applications. The trial is part of the company’s ongoing efforts to explore new treatment avenues within the pharmaceutical sector.
Radiopharm Theranostics is registered under the standard industrial classification for pharmaceutical preparations and operates out of Carlton, Victoria, Australia. The company is incorporated in the state of C3 and reports under the fiscal year ending June 30.
The information regarding this development was sourced from a Form 6-K filed with the U.S. Securities and Exchange Commission. The filing emphasized that the report is not deemed "filed" for purposes of the Securities Exchange Act of 1934 and is not incorporated by reference into any filings under the Securities Act of 1933, unless specifically stated.
Phillip Hains, the company secretary, signed the report on behalf of Radiopharm Theranostics. The company continues to focus on advancing its pipeline of radiopharmaceuticals, with 177Lu-RAD202 being a key component of its research and development efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.